K2 Medical Research and TPG Establish Partnership to Build a Leading Integrated Site Platform

SAN FRANCISCO & ORLANDO, Fla.–(BUSINESS WIRE)–TPG (NASDAQ: TPG), a leading global alternative asset management firm, today announced a significant strategic growth investment in K2 Medical Research (“K2” or the “Company”), an integrated clinical trial site platform specializing in central nervous system (CNS) trials for leading pharma and biotech sponsors. TPG is partnering with K2’s management team to continue building a world class research platform. Terms were not disclosed. Founded by Chi
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks